Skip to main content
SpringerLink
Log in

Pituitary Hypogonadism, Hyperprolactinemia, and Gonadotropin-Producing Tumors

  • Chapter
  • First Online:
Andrology

  • 542 Accesses

Abstract

Pituitary-induced hypogonadism may be hereditary or acquired. In most cases, adenomas are the cause of pituitary-induced hypogonadism. Adenomas can be treated with medication and/or neurosurgery. This often results in the restoration of function of at least some hormonal axes. In general, in cases of pituitary insufficiency that cannot be treated causally, the hormone at the end of the signal chain is substituted, in men this is testosterone. Subsequently, the administration of thyroid hormones, cortisol, and, if necessary, growth hormone must be considered. If the neurohypophysis fails, ADH is administered. An exception to the otherwise usual testosterone administration is when progeny is desired. Here, testicular function with sufficient testosterone production and spermatogenesis must be induced or maintained by administration of gonadotropins.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Berezin M, Karasik A (1995) Familial prolactinoma. Clin Endocrinol 42:483–486

    CAS  Google Scholar 

  • Bevan JS, Webster J, Burke C, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220–240

    CAS  PubMed  Google Scholar 

  • Biagetti B, Ferrer Costa R, Alfayate Guerra R, Álvarez García E, Berlanga Escalera E, Casals G, Esteban Salán M, Granada Ibern ML, Gorrín Ramos J, López Lazareno N, Oriola J, Sánchez Martínez PM, Torregrosa Quesada ME, Urgell Rull E, García Lacalle C (2022) Macroprolactin: From laboratory to clinical practice. Endocrinol Diabetes Nutr (Engl Ed) 69:63–69

    PubMed  Google Scholar 

  • Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Investig 22:354–359

    CAS  Google Scholar 

  • Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006) Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273

    Google Scholar 

  • Castinetti F, Albarel F, Amodru V, Cuny T, Dufour H, Graillon T, Morange I, Brue T (2021) The risks of medical treatment of prolactinoma. Ann Endocrinol (Paris) 82(1):15–19

    PubMed  Google Scholar 

  • Chaidarun SS, Klibanski A (2002) Gonadotropinomas. Semin Reprod Med 20:339–348

    PubMed  Google Scholar 

  • Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033

    CAS  PubMed  Google Scholar 

  • Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D’Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G (2008) Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777–3784

    CAS  PubMed  Google Scholar 

  • Dai C, Liang S, Sun B, Kang J (2020) The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas. Front Endocrinol (Lausanne) 11:608422

    PubMed  Google Scholar 

  • De Rosa M, Colao A, Di Sarno A, Ferone D, Landi ML, Zarrilli S, Paesano L, Merola B, Lombardi G (1998) Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 138:286–293

    PubMed  Google Scholar 

  • Deladoey J, Flück C, Büyükgebiz A, Kuhlmann BV, Eblé A, Hindmarsh PC, Wu W, Mullis PE (1999) "Hot spot" in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab 84:1645–1650

    CAS  PubMed  Google Scholar 

  • Dwyer AA, Raivio T, Pitteloud N (2015) Gonadotrophin replacement for induction of fertility in hypogonadal men. Best Pract Res Clin Endocrinol Metab 29:91–103

    CAS  PubMed  Google Scholar 

  • Flück C, Deladoey J, Rutishauser K, Eblé A, Marti U, Wu W, Mullis PE (1998) Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg → Cys at codon 120 (R120C). J Clin Endocrinol Metab 83:3727–3734

    PubMed  Google Scholar 

  • Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485–534

    CAS  PubMed  Google Scholar 

  • Haider SA, Levy S, Rock JP, Craig JR (2022) Prolactinoma: Medical and surgical considerations. Otolaryngol Clin N Am 55(2):305–314

    Google Scholar 

  • Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol 70:104–108

    Google Scholar 

  • Ilie MD, Raverot G (2020) Treatment options for gonadotroph tumors: current state and perspectives. J Clin Endocrinol Metab 105:dgaa497

    PubMed  Google Scholar 

  • Inder WJ, Jang C (2022) Treatment of prolactinoma. Medicina (Kaunas) 58:1095

    PubMed  Google Scholar 

  • Jaffe CA (2006) Clinically non-functioning pituitary adenoma. Pituitary 9:317–321

    PubMed  Google Scholar 

  • Karavitaki N, Thanabalasingham G, Shore HC, Trifanescu R, Ansorge O, Meston N, Turner HE, Wass JA (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 65:524–529

    CAS  Google Scholar 

  • Kars M, Pereira AM, Bax JJ, Romijn JA (2008) Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 159:363–367

    CAS  PubMed  Google Scholar 

  • Kelberman D, Dattani MT (2008) Septo-optic dysplasia - novel insights into the aetiology. Horm Res 69:257–265

    CAS  PubMed  Google Scholar 

  • Lagerström-Fermér M, Sundvall M, Johnsen E, Warne GL, Forrest SM, Zajac JD, Rickards A, Ravine D, Landegren U, Pettersson U (1997) X-linked recessive panhypopituitarism associated with a regional duplication in Xq25-q26. Am J Hum Genet 60:910–916

    PubMed  PubMed Central  Google Scholar 

  • Lee DH, Park JE, Nam YK, Lee J, Kim S, Kim YH, Kim HS (2021) Deep learning-based thin-section MRI reconstruction improves tumour detection and delineation in pre- and post-treatment pituitary adenoma. Sci Rep 29:21302

    Google Scholar 

  • Liu PY, Baker HWG, Jayadev V (2009) Induction of spermatogenesis and fertility during gonadotropin treatment of Gonadotropin-Deficient infertile men: predictors of fertility outcome. J Clin Endocrinol Metab 94:801–808

    CAS  PubMed  Google Scholar 

  • Lofrano-Porto A, Casulari LA, Nascimento PP, Giacomini L, Naves LA, da Motta LD, Layman LC (2008) Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone beta subunit mutation. Fertil Steril 90:1169–1174

    PubMed  Google Scholar 

  • Lüdecke DK für die Expertengruppe der Arbeitsgemeinschaft Hypophyse (2003) Betreuung von Patienten mit hormoninaktiven Adenomen der Hypophyse. Med Klin 98:616–627

    Google Scholar 

  • Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109:42–50

    CAS  PubMed  Google Scholar 

  • Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin N Am 37:67–99

    CAS  Google Scholar 

  • Mantovani G, Borgato S, Beck-Peccoz P, Romoli R, Borretta G, Persani L (2003) Isolated follicle-stimulating hormone (FSH) deficiency in a young man with normal virilization who did not have mutations in the FSHbeta gene. Fertil Steril 79:434–436

    PubMed  Google Scholar 

  • Mehta A, Dattani MT (2008) Developmental disorders of the hypothalamus and pituitary gland associated with congenital hypopituitarism. Best Pract Res Clin Endocrinol Metab 22:191–206

    CAS  PubMed  Google Scholar 

  • Melmed S (2008) Update in pituitary disease. J Clin Endocrinol Metab 93:331–338

    CAS  PubMed  Google Scholar 

  • Müller OA, Emons G, Fahlbusch F, Hensen J, Ranke MB, Stalla GK, Strasburger CJ (2003) Hypothalamus und Hypophyse. In: Deutsche Gesellschaft für Endokrinologie (ed) Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel, 2nd edn. Thieme, New York, pp 7–44

    Google Scholar 

  • Nachtigall LB (2017) Cabergoline for hyperprolactinemia: getting to the heart of it. Endocrine 57:3–5

    CAS  PubMed  Google Scholar 

  • Oduwole OO, Peltoketo H, Poliandri A, Vengadabady L, Chrusciel M, Doroszko M, Samanta L, Owen L, Keevil B, Rahman NA, Huhtaniemi IT (2018) Constitutively active follicle-stimulating hormone receptor enables androgen-independent spermatogenesis. J Clin Invest 128:1787–1792

    PubMed  PubMed Central  Google Scholar 

  • Pasqualini RQ, Burr GE (1950) Sindrome hypoandrogenico con gametogenesis conservada. Classification del la insufficiencia testicular. Rev Asoc Med Argent 64:6–19

    Google Scholar 

  • Pitteloud N, Boepple PA, DeCruz S, Valkenburgh SB, Crowley WF Jr, Hayes FJ (2001) The fertile eunuch variant of idiopathic hypogonadotropic hypogonadism: spontaneous reversal associated with a homozygous mutation in the gonadotropin-releasing hormone receptor. J Clin Endocrinol Metab 86:2470–2475

    CAS  PubMed  Google Scholar 

  • Rastrelli G, Corona G, Maggi M (2015) The role of prolactin in andrology: what is new? Rev Endocr Metab Disord 16:233–248

    CAS  PubMed  Google Scholar 

  • Rohayem J, Hauffa BP, Zacharin M, Kliesch S, Zitzmann M, German Adolescent Hypogonadotropic Hypogonadism Study Group (2017) Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? -a multicentre prospective study of hCG/rFSH treatment outcomes during adolescence. Clin Endocrinol 86:75–87

    CAS  Google Scholar 

  • Rosenbloom AL, Almonte SA, Brown MR, Fisher DA, Baumbach L, Parks JS (1999) Clinical and biochemical phenotype of familial anterior hypopituitarism from mutations of the PROP1 gene. J Clin Endocrinol Metab 84:50–57

    CAS  PubMed  Google Scholar 

  • Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156:203–216

    CAS  PubMed  Google Scholar 

  • Schlechte JA (2003) Clinical practice. Prolactinoma. N Engl J Med 349:2035–2041

    CAS  PubMed  Google Scholar 

  • Schlechte JA (2007) Long-term management of prolactinoma. J Clin Endocrinol Metab 92:2861–2865

    CAS  PubMed  Google Scholar 

  • Shaid M, Korbonits M (2017) Genetics of pituitary adenomas. Neurol India 65:577–587

    PubMed  Google Scholar 

  • Sherlock M, Toogood AA, Steeds R (2009) Dopamine agonist therapy for hyperprolactinaemia and cardiac valve fibrosis; a lot done but much more to do. Heart 95(7):522–523

    CAS  PubMed  Google Scholar 

  • Solomon NM, Ross SA, Morgan T, Belsky JL, Hol FA, Karnes PS, Hopwood NJ, Myers SE, Tan AS, Warne GL, Forrest SM, Thomas PQ (2004) Array comparative genomic hybridisation analysis of boys with X linked hypopituitarism identifies a 3.9 Mb duplicated critical region at Xq27 containing SOX3. J Med Genet 41:669–678

    CAS  PubMed  PubMed Central  Google Scholar 

  • von Werder K (1995) Alte und neue Therapieoptionen bei der Hyperprolaktinämie. In: Allolio B, Grußendorf M, Müller OA, Olbricht T, Schulte HM (eds) Syllabus des III. Intensivkursus für Klinische Endokrinologie. Bundesdruckerei, Neu-Isenburg, pp 108–115

    Google Scholar 

  • Willnow S, Kiess W, Butenandt O, Dörr HG, Enders A, Strasser-Vogel B, Egger J, Schwarz HP (1996) Endocrine disorders in septo-optic dysplasia (De Morsier syndrome) - evaluation and follow-up of 18 patients. Eur J Pediatr 155:179–184

    CAS  PubMed  Google Scholar 

  • Yao A, Rutland JW, Verma G, Banihashemi A, Padormo F, Tsankova NM, Delman BN, Shrivastava RK, Balchandani P (2020) Pituitary adenoma consistency: direct correlation of ultrahigh field 7T MRI with histopathological analysis. Eur J Radiol 126:108931

    PubMed  Google Scholar 

  • Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Reproductive Medicine and Andrology, University Hospital Münster, Münster, Germany

    Michael Zitzmann

  2. Center for Reproductive Medicine and Andrology, University Hospital Halle (Saale), Halle (Saale), Germany

    Hermann M. Behre

Authors
  1. Michael Zitzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hermann M. Behre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Zitzmann .

Editor information

Editors and Affiliations

  1. Center for Reproductive Medicine and Andrology, University Hospital Münster, Münster, Germany

    Eberhard Nieschlag

  2. Center for Reproductive Medicine and Andrology, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

    Hermann M. Behre

  3. Center for Reproductive Medicine and Andrology, University Hospital Münster, Münster, Germany

    Sabine Kliesch

  4. Center for Reproductive Medicine and Andrology, University Hospital Münster, Münster, Germany

    Susan Nieschlag

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zitzmann, M., Behre, H.M. (2023). Pituitary Hypogonadism, Hyperprolactinemia, and Gonadotropin-Producing Tumors. In: Nieschlag, E., Behre, H.M., Kliesch, S., Nieschlag, S. (eds) Andrology. Springer, Cham. https://doi.org/10.1007/978-3-031-31574-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-31574-9_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-31573-2

  • Online ISBN: 978-3-031-31574-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation